

Enbrel - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review

PLEASE NOTE: Any inic	rmation (patient, prescriber, drug, ia	bs) left blank, illegible, or not attached will delay the review process.
Patient Name:		Prescriber Name:
Member Number:		Fax: Phone:
Date of Birth:		Office Contact:
Line of Business:		NPI: State Lic ID:
Address:		Address:
City, State ZIP:		City, State ZIP:
Primary Phone:		Specialty/facility name (if applicable):
	: By checking this box and signing below, I denrollee's ability to regain maximum functi	certify that applying the 72 hour standard review timeframe may seriously jeopardize ion.
Strength:		
Directions / SIG:		
Discount of the second of		
Please attach any pertin		s and information for this member that may support approval. Iowing questions and sign.
Q1. Is this a reauthori	zation request?	
☐ Yes - Go to 2		☐ No - Go to 3
Q2. Is there confirmat	ion of continued positive cl	linical response since starting Enbel?
☐ Yes		□No
Q3. Does the patient I	nave the diagnosis of rheu	matoid arthritis or psoriatic arthritis?
☐ Yes		□ No
Q4. Is the patient 18 y	ears of age or older?	
☐ Yes		□ No
one or more disease r	modifying antirheumatic dru	nse, intolerance or contraindication to at least ugs (DMARDs) (e.g., for RA: azathioprine, ne, methotrexate and for PsA: leflunomide,
☐ Yes		□No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



Enbrel - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
Q6. Does the patient have the diagnosis of plaque psoriasis? If No, go to 11.		
□ Yes	□ No	
Q7. Is the patient 4 years of age or older?		
□ Yes	□ No	
Q8. Is the disease moderate to severe?		
☐ Yes	□ No	
Q9. Is there documentation of inadequate response, intolerance or contraindication to methotrexate OR ultraviolet-B (UVB) therapy (alone or in combination with other medications) OR acitretin (requires prior authorization)? If Yes, go to 18.		
☐ Yes	□ No	
Q10. Is there documentation of inadequate response, intolerance or contraindication to one topical steroid (high to very high potency) AND calcipotriene 0.005% cream? If Yes, go to 18.		
☐ Yes	□ No	
Q11. Does the patient have the diagnosis of polyarticular juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA)? If No, go to 14.		
☐ Yes	□ No	
Q12. Is the patient 2 years of age or older?		
☐ Yes	□ No	
Q13. Is there documentation of inadequate response, intolerance or contraindication to one or more disease modifying anti-rheumatic drug (DMARD) OR is intolerant to DMARDS (e.g., sulfasalazine, methotrexate)? If Yes, go to 17.		
□ Yes	□ No	
Q14. Does the patient have the diagnosis of ankylosing spondylitis?		



Enbrel - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	
Q15. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q16. Is there documentation of inadequate response, intolerance or contraindication to at least two or more non-steroidal anti-inflammatory drugs (NSAIDs) OR is intolerant to NSAIDs?		
☐ Yes	□ No	
Q17. Is Enbrel being prescribed by or in consultation with a rheumatologist?		
☐ Yes	□ No	
Q18. Is Enbrel being prescribed by or in consultation with a dermatologist?		
☐ Yes	□ No	
Q19. Has the patient been evaluated for active or latent tuberculosis (TB) infection with a tuberculin skin test prior to the initiation of therapy?		
☐ Yes	□ No	
Q20. Was the tuberculin skin test negative?		
☐ Yes	□ No	
Q21. Has the patient received appropriate prophylaxis in accordance with Centers for Disease Control and Prevention (CDC) guidelines?		
☐ Yes	□ No	
Q22. Requested Duration:		
☐ 12 months	☐ Other	
Q23. Additional Information:		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



Enbrel - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, lilegible, or not attached will delay the review process.		
Patient Name:	Prescriber Name:	
Prescriber Signature	Date	
	2024 Medicare Prior Authorization Request	